NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 1 நாளுக்கு முன்இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
GKSL Reports Q2 FY27 Revenue of ₹38.1 Cr, H1 Revenue Surges 157% to ₹72.4 Cr
Gujarat Kidney and Super Speciality Limited (GKSL) conducted its Q2 and H1 FY27 earnings call, highlighting significant operational scale-up through acquisitions. Consolidated revenue for H1 FY27 reached ₹72.4 crore (up 157% YoY), while Q2 FY27 revenue stood at ₹38.1 crore with a PAT of ₹6.6 crore. However, EBITDA margins contracted from historical levels (~48% in H1 FY26) to 25.7% in H1 FY27 due to newly acquired hospital integrations and higher employee costs from Dubai operations. The company maintains net cash with ₹32.2 crore in cash and bank balances against borrowings of ₹17.3 crore.
உச்சம் நம்பிக்கை
என்ன மாறியதுGKSL shared its maiden post-listing earnings call transcript, discussing operating performance across its 11 hospitals and the integration of acquired assets.
ஏன் இது முக்கியம்While top-line growth is accelerating rapidly via M&A, the sharp dilution in EBITDA margins and working capital drag on cash flows highlight integration challenges.
📅 குறுகிய காலம்Market focus will likely center on margin compression from acquired assets and the significant divergence between H1 net profit (₹11.9 crore) and operating cash flow (₹0.4 crore).
📈 நீண்ட காலம்Success hinges on GKSL's ability to drive bed occupancy above 65%, improve low ARPOB (₹9,221/day), and cross-sell high-margin surgical specialties across newly added hospitals.
⚠ அபாய எச்சரிக்கைகள்
Margin compression due to higher operating and employee costs from Dubai operations
Weak operating cash flow conversion (₹0.4 crore OCF vs ₹11.9 crore PAT in H1 FY27)
Execution and integration risks from aggressive inorganic expansion
👀 கவனிக்க வேண்டியவை
Monitor how quickly operating cash flows recover (reported at just ₹0.4 crore for H1 vs PAT of ₹11.9 crore) and whether EBITDA margins stabilize above 26% as acquired hospitals scale up.
GKSL Reports Q2 FY27 PAT of ₹6.60 Cr (+129% YoY), Revenue Jumps 195% to ₹38.09 Cr
Gujarat Kidney And Super Speciality Limited (GKSL) released its Q2 FY27 investor presentation, reporting a 194.6% YoY jump in revenue from operations to ₹3,809 lakhs (₹38.09 crore). EBITDA for the quarter rose 99.4% YoY to ₹1,022 lakhs with a 26.8% margin, while PAT grew 129.4% YoY to ₹660 lakhs. Growth was driven by aggressive inorganic expansion, with ₹1,669 lakhs deployed towards acquisitions in H1 FY27, taking total network capacity to 11 hospitals and 700 beds across central Gujarat.
உச்சம் நம்பிக்கை
என்ன மாறியதுGKSL published its Q2 FY27 financial presentation detailing consolidated revenue of ₹38.09 crore and updates on recent regional hospital acquisitions.
ஏன் இது முக்கியம்The company is rapidly transitioning from a single-city hospital to an inorganic regional healthcare platform in Gujarat, substantially scaling revenues and bed capacity.
Q2 FY27 Revenue: ₹3,809 லட்சம்Q2 FY27 PAT: ₹660 லட்சம்Q2 FY27 EBITDA Margin: 26.8%Goodwill as of Sep 2026: ₹10,742 லட்சம்H1 FY27 Acquisitions Spend: ₹1,669 லட்சம்
📅 குறுகிய காலம்Earnings show sharp revenue and profit momentum driven by consolidation of acquired units, likely supporting positive investor sentiment.
📈 நீண்ட காலம்Structural success depends on successfully integrating multiple small regional hospitals, maintaining clinical quality, and driving occupancy beyond 55% without diluting return ratios.
⚠ அபாய எச்சரிக்கைகள்
High goodwill on balance sheet (₹107.42 crore vs ₹263.64 crore net worth) from aggressive acquisitions
Geographic concentration risk remains within central Gujarat
Operating cash flow remains low at ₹42 lakhs for H1 FY27 relative to PAT of ₹1,192 lakhs
👀 கவனிக்க வேண்டியவை
Track operational integration of newly acquired hospitals, bed occupancy rates (currently ~55%), and whether cash flows improve sustainably after H1 FY27 operating cash flow of ₹42 lakhs.
Gujarat Kidney And Super Speciality Limited (GKSL) has approved its unaudited standalone and consolidated financial results for the quarter ended September 30, 2026. Statutory auditors M/s. Y M Shah & Co. submitted a Limited Review Report with an unmodified opinion. The board meeting concluded at 6:00 PM on November 4, 2026, with detailed XBRL financial metrics submitted separately. In Q1 FY27 (June 2026), the company had posted revenue of Rs 34.29 cr and net profit of Rs 5.32 cr.
நடுத்தரம் நம்பிக்கை
என்ன மாறியதுFormal approval and submission of Q2 FY27 quarterly financial results with clean audit review.
ஏன் இது முக்கியம்Confirms periodic compliance and clean statutory audit review; actual operational performance depends on the accompanying detailed income statement and balance sheet.
Quarter ended: செப்டம்பர் 30, 2026Audit opinion: unmodifiedPrior quarter revenue (Jun 2026): Rs 34.2892 கோடிPrior quarter PAT (Jun 2026): Rs 5.321 கோடி
📅 குறுகிய காலம்Market reaction will depend on the revenue, margin, and PAT numbers disclosed in the detailed financial annexures.
📈 நீண்ட காலம்Limited from this procedural outcome; structural trajectory depends on hospital occupancy and geographic expansion beyond Vadodara.
⚠ அபாய எச்சரிக்கைகள்
100% geographic concentration in Vadodara, Gujarat
Detailed P&L figures not included directly in the outcome letter
👀 கவனிக்க வேண்டியவை
Track the detailed XBRL financial annexure once uploaded to assess Q2 revenue and PAT trajectory relative to Q1 FY27 (revenue of Rs 34.29 cr and net profit of Rs 5.32 cr).
Gujarat Kidney And Super Speciality Limited has submitted its unaudited standalone and consolidated financial results for the first quarter ended June 30, 2026. The independent statutory auditor, Y. M. Shah & Co., has issued an unmodified limited review report confirming compliance with Ind AS 34. The detailed P&L table was not included in the review report extract, but the submission satisfies quarterly regulatory compliance under Regulation 33. Investors should review the complete financial table once fully accessible on the exchange.
நடுத்தரம் நம்பிக்கை
என்ன மாறியதுThe company completed its quarterly board review and submitted standalone and consolidated limited review reports for Q1 ended June 30, 2026.
ஏன் இது முக்கியம்Provides regular regulatory disclosure and confirms from independent auditors that interim financial statements carry no material misstatements.
📅 குறுகிய காலம்Neutral trading expected as the filing represents routine quarterly results compliance without immediate auditor qualifications.
📈 நீண்ட காலம்Limited direct impact from the review report alone; long-term performance hinges on hospital bed additions, NABH-driven pricing power, and geographic diversification beyond Vadodara.
⚠ அபாய எச்சரிக்கைகள்
High geographic concentration risk with operations focused in Vadodara, Gujarat
Detailed profit and loss statement numbers omitted from the auditor report text extract
👀 கவனிக்க வேண்டியவை
Track the full quarterly financial tables on the exchange to assess revenue growth, bed occupancy, and operating margins compared to previous quarters.
₹19.84 Cr Acquisition: GKSL to Acquire 51% Stake in UAE-based Blue Tree Clinics LLC
Gujarat Kidney And Super Speciality Limited (GKSL) has entered into a Share Purchase Agreement to acquire a 51% majority stake in Blue Tree Clinics LLC, a Dubai-based polyclinic, for ₹19.84 crore. This acquisition marks a significant strategic shift, moving the company beyond its 100% geographic concentration in Vadodara, Gujarat, into the UAE market. The target entity is profitable, reporting a net profit of 3.14 million AED (~₹7.1 crore) on a revenue of 10.54 million AED (~₹23.9 crore) for FY 2025. The acquisition cost of ₹19.84 crore is substantial, representing approximately 153% of GKSL's reported Dec 2025 quarterly revenue of ₹12.93 crore.
உச்சம் நம்பிக்கை
என்ன மாறியதுGKSL is transforming from a regional, kidney-focused hospital in Vadodara to an international healthcare provider with a presence in Dubai and a broader range of medical services.
ஏன் இது முக்கியம்This acquisition significantly scales the business, as the target's annual revenue is nearly half of GKSL's estimated annual run rate. It also mitigates the risk of 100% geographic concentration in Gujarat by entering the high-margin UAE healthcare market.
Acquisition Cost: ₹19,83,64,500Stake Acquired: 51%Target Revenue (FY25): 10,538,978 AEDTarget Net Profit (FY25): 3,138,809 AEDAcquisition Cost vs Dec-25 Qtr Revenue: 153.4%Completion Timeline: 50 நாட்கள்
📅 குறுகிய காலம்The stock is likely to react positively to the international expansion and the acquisition of a profitable entity with high margins.
📈 நீண்ட காலம்If successfully integrated, this provides a structural growth lever and diversifies the company's revenue streams away from pure nephrology into high-demand cosmetic and dental services.
⚠ அபாய எச்சரிக்கைகள்
Integration risk in a foreign jurisdiction (UAE)
Diversification into unrelated medical fields (Cosmetic/Dental)
Variation in IPO objects suggests a shift from original business plans
👀 கவனிக்க வேண்டியவை
Monitor the upcoming Postal Ballot for details on how IPO proceeds are being reallocated for this acquisition. Investors should also track the 50-day completion timeline and the subsequent impact on consolidated margins given the target's ~30% net profit margin.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
GKSL Shareholders Approve Variation in IPO Proceeds Utilization with 99.99% Majority
Shareholders of Gujarat Kidney And Super Speciality Limited (GKSL) have passed a special resolution to vary the objects or terms of utilization of its Initial Public Offering (IPO) proceeds. The resolution received overwhelming support with 99.9995% of the votes cast in favor. A total of 56,894,985 votes were polled, representing a 72.16% turnout of the total 78,843,250 shares. This approval grants the management flexibility to redirect capital raised during the IPO toward revised corporate priorities.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has obtained formal shareholder approval to deviate from the original fund utilization plan outlined in its IPO prospectus.
ஏன் இது முக்கியம்Changing the use of IPO proceeds is a significant event that can alter the company's growth trajectory, debt profile, or expansion timelines compared to what was promised at the time of listing.
Total Votes Polled: 56,894,985Votes in Favor: 56,894,699Percentage in Favor: 99.9995%Promoter Votes: 56,333,900Public Turnout: 2.9992%
📅 குறுகிய காலம்Neutral. The market will likely wait for specific disclosures on how the redirected funds are deployed before reacting significantly.
📈 நீண்ட காலம்The impact depends on whether the new allocation of funds generates higher returns than the original objects stated in the IPO prospectus.
⚠ அபாய எச்சரிக்கைகள்
Deviation from original IPO prospectus
High promoter concentration in voting results
Low public shareholder participation
👀 கவனிக்க வேண்டியவை
Investors should review the specific details of the 'variation' mentioned in the May 28, 2026 notice to understand exactly how the capital is being redirected and if it aligns with the company's kidney-care growth strategy.
GKSL Seeks Shareholder Approval to Reallocate ₹37.76 Cr of IPO Proceeds
Gujarat Kidney And Super Speciality Limited (GKSL) has issued a postal ballot notice to vary the utilization of its IPO proceeds. The company intends to reallocate ₹37.76 Cr of unutilized funds, shifting focus from a specific Bharuch hospital project to broader healthcare expansion and inorganic growth. Notably, ₹19.02 Cr is being moved to the 'Funding inorganic growth and general corporate purposes' category, significantly increasing that bucket to ₹31.64 Cr. This move provides the management with greater flexibility for unidentified acquisitions and infrastructure upgrades across the parent and subsidiary companies.
முக்கிய அம்சங்கள்
Seeking special resolution to reallocate ₹37.76 Cr of unutilized IPO proceeds₹25.14 Cr originally for a Bharuch project is being repurposed for broader infrastructure and equipment₹19.02 Cr transferred to 'Inorganic growth and general corporate purposes', bringing that total to ₹31.64 Cr₹6.12 Cr specifically earmarked for modern equipment and facilities in parent and subsidiary unitsRemote e-voting period for shareholders is set from June 5, 2026, to July 4, 2026
👀 கவனிக்க வேண்டியவை
Investors should monitor how the company utilizes the increased ₹31.64 Cr pool for inorganic growth, as the shift away from a specific project to unidentified acquisitions introduces execution risk. Evaluate if the new allocation toward general corporate purposes aligns with long-term value creation compared to the original IPO plan.
GKSL Reports 14% Revenue Growth in FY26; Proposes Variation in IPO Objects
Gujarat Kidney And Super Speciality Limited (GKSL) reported a steady financial performance for FY26, with revenue from operations rising to ₹40.10 crore from ₹35.17 crore in FY25. Net profit saw a modest increase of 8.7% to ₹9.90 crore, though EPS dipped slightly to 1.59 due to a significant expansion in the equity base. Notably, the company is seeking shareholder approval to vary the objects of its IPO proceeds and has deferred the appointment of a new CEO.
முக்கிய அம்சங்கள்
Annual revenue from operations grew 14% YoY to ₹4,010.02 Lacs in FY26.Net profit for the full year increased to ₹990.14 Lacs compared to ₹910.90 Lacs in FY25.Total Equity surged significantly to ₹24,645.86 Lacs from ₹2,541.56 Lacs, reflecting post-IPO capital structure.The Board has deferred the agenda for the appointment of a Chief Executive Officer (CEO).A Postal Ballot will be conducted to seek approval for a Special Resolution regarding the variation in IPO objects.
👀 கவனிக்க வேண்டியவை
Investors should closely monitor the upcoming Postal Ballot details to understand why IPO funds are being redirected and track the deferred CEO appointment as a key leadership signal.
GKSL FY26 PAT Rises to ₹9.90 Cr; CEO Appointment Deferred; IPO Object Variation Proposed
Gujarat Kidney And Super Speciality Limited (GKSL) reported a 14% growth in annual revenue to ₹40.10 crore for FY26, with net profit increasing to ₹9.90 crore. The company has deferred the appointment of a CEO, leaving a key leadership position vacant for now. Notably, the board is seeking shareholder approval to vary the objects of its IPO, suggesting a change in how recently raised capital will be utilized. Total equity saw a massive jump to ₹246.46 crore, likely reflecting the impact of the IPO proceeds.
முக்கிய அம்சங்கள்
Annual Revenue from Operations grew 14% YoY to ₹4,010.02 Lacs in FY26 compared to ₹3,516.70 Lacs in FY25.Net Profit (PAT) for the year increased to ₹990.14 Lacs from ₹910.90 Lacs in the previous fiscal.The Board of Directors deferred the agenda for the appointment of a Chief Executive Officer (CEO).Proposed a Special Resolution via Postal Ballot for 'Variation in Objects of IPO', indicating a shift in capital allocation strategy.Appointed Mr. Siddharth Atulbhai Shah as Internal Auditor and SPANJ & Associates as Secretarial Auditor for a 5-year term.
👀 கவனிக்க வேண்டியவை
Investors should seek clarity on the proposed 'Variation in Objects of IPO' as it indicates a change in the company's original growth or debt-repayment plans. Monitor the eventual CEO appointment to assess future leadership stability.
GKSL FY26 Net Profit Rises 8.7% to ₹9.9 Cr; Board to Vary IPO Objects
Gujarat Kidney And Super Speciality Limited (GKSL) reported a steady financial performance for FY26, with annual revenue reaching ₹40.10 crore compared to ₹35.17 crore in FY25. Net profit for the year grew to ₹9.90 crore, up from ₹9.11 crore in the previous fiscal. The company's balance sheet saw a massive expansion, with total assets jumping to ₹266.08 crore from ₹49.07 crore, primarily driven by post-IPO capital. However, the board has deferred the CEO appointment and is seeking shareholder approval to change the utilization of IPO proceeds.
முக்கிய அம்சங்கள்
Annual Revenue from Operations grew 14% YoY to ₹4,010.02 Lacs in FY26.Net Profit for the full year increased to ₹990.14 Lacs from ₹910.90 Lacs in FY25.Total Assets surged to ₹26,607.67 Lacs, reflecting a significant increase in equity and investments post-listing.Board proposed a Postal Ballot for a Special Resolution regarding 'Variation in Objects of IPO'.The appointment of a new CEO has been deferred by the Board of Directors.
👀 கவனிக்க வேண்டியவை
Investors should closely monitor the details of the postal ballot regarding the variation in IPO objects to understand how the company plans to reallocate its capital. While earnings growth is stable, the deferred CEO appointment and change in fund utilization suggest a transitional phase for management.
GKSL to Deploy 100 AI-Powered Haemodialysis Machines; First 8 Units Live in 10 Days
Gujarat Kidney And Super Speciality Limited (GKSL) has announced a major capacity expansion by procuring 100 AI-enabled Haemodialysis machines. The first phase involves commissioning 8 units at its Godhra facility within 10 days, following successful technical inspections. This move integrates advanced AI technology for real-time patient data analysis, which is expected to improve clinical outcomes and operational efficiency. The remaining units will be deployed across the company's network in a phased manner to meet growing demand for renal care in Gujarat.
முக்கிய அம்சங்கள்
Procurement of 100 AI-powered Haemodialysis machines to scale up renal care servicesPhase 1 deployment of 8 machines at Gujarat Multi Speciality Hospital, Godhra, within 10 daysAI technology enables real-time decision support and early detection of intradialytic complicationsStrategic rollout planned across the network to increase session capacity and regional reach
👀 கவனிக்க வேண்டியவை
Investors should monitor the execution of the phased rollout as it is likely to drive higher patient volumes and improve the company's competitive positioning in specialized renal care. The adoption of AI technology may also lead to better clinical reputations and potentially higher margins over time.
GKSL to Incorporate New Subsidiary for Bharuch Expansion and Appoints New CS
Gujarat Kidney And Super Speciality Limited (GKSL) has approved the incorporation of a Wholly Owned Subsidiary (WOS) to expand its healthcare footprint into the Bharuch district of Gujarat. The company received shareholder approval via postal ballot to utilize IPO funds for this healthcare expansion. Additionally, the board approved a voluntary revision of financial statements under Section 131 of the Companies Act, indicating a correction in previous reporting. Ms. Vishakha Mahesh Phadke has been appointed as the new Company Secretary and Compliance Officer to strengthen corporate governance.
முக்கிய அம்சங்கள்
Approved incorporation of a Wholly Owned Subsidiary (WOS) with an initial nominal capital of ₹1,00,000.Expansion targeted at Bharuch district, adding to existing presence in Vadodara, Dahod, Ahmedabad, and Godhara.Shareholders passed a special resolution for interim utilization of IPO funds towards healthcare expansion.Board approved voluntary revision of Financial Statements and Board's report under Section 131 of the Companies Act.Appointment of Ms. Vishakha Mahesh Phadke as Company Secretary and Compliance Officer effective April 27, 2026.
👀 கவனிக்க வேண்டியவை
Investors should view the expansion into Bharuch as a positive growth move, but should also seek clarity on the reasons for the voluntary revision of financial statements. Monitor the timeline for the new subsidiary's operational launch, expected by the end of H1 FY 2026-27.
GKSL Shareholders Approve Healthcare Expansion Funds and Financial Statement Revision
Gujarat Kidney and Super Speciality Limited (GKSL) has announced the successful passage of three key resolutions via postal ballot with near-unanimous support. Shareholders approved the interim utilization of funds for healthcare expansion, aligning with the company's IPO objectives. Notably, a special resolution for the voluntary revision of financial statements and the Board's report under Section 131 of the Companies Act was also passed. Additionally, the company confirmed the appointment of Mr. Dharmendra Bhaliya as the Secretarial Auditor for the 2025-26 fiscal year.
முக்கிய அம்சங்கள்
Resolution for healthcare expansion fund utilization passed with 100% of 5,68,46,254 valid votes in favor.Voluntary revision of Financial Statements and Board's Report approved with a 99.9998% majority.Total voter participation represented 72.10% of the company's total outstanding shares.Appointment of Mr. Dharmendra Bhaliya as Secretarial Auditor for FY 2025-26 was finalized with 99.9994% approval.
👀 கவனிக்க வேண்டியவை
Investors should monitor the specific reasons for the voluntary revision of financial statements to ensure there are no underlying accounting or governance concerns. While the expansion plan is a positive growth indicator, the regulatory revision warrants a cautious approach.
GKSL to Reallocate ₹3192.5 Lakhs IPO Funds and Revise Past Financial Statements
Gujarat Kidney And Super Speciality Limited (GKSL) has issued a postal ballot seeking shareholder approval to significantly reallocate IPO proceeds. The company plans to divert ₹2510 lakhs originally intended for a Vadodara hospital toward a new multispeciality project in Bharuch and ₹682.50 lakhs toward a dialysis services collaboration. Furthermore, the company is voluntarily revising its financial statements and Board's reports for FY 2021-22, 2022-23, and 2023-24 following an NCLT order to ensure proper disclosure compliance.
முக்கிய அம்சங்கள்
Reallocation of ₹3010 lakhs from a proposed Vadodara hospital to a new multispeciality hospital project in Bharuch.Diversion of ₹682.50 lakhs from robotics equipment to establish dialysis services in collaboration with Lord’s Mark Industries Limited.Voluntary revision of financial statements and notes for three consecutive years (FY22 to FY24) as per NCLT order dated Feb 6, 2026.Utilization of ₹1262 lakhs from General Corporate Purposes to fund the revised healthcare expansion objects.Remote e-voting for these resolutions is scheduled from March 27, 2026, to April 25, 2026.
👀 கவனிக்க வேண்டியவை
Investors should closely examine the reasons for the geographic shift in expansion and the implications of the voluntary financial revisions on the company's historical performance data. Monitor the progress of the new Bharuch project as it replaces the original IPO objective.
GKSL Q2 FY26 Results: Revenue Up 2.5% to ₹9.64 Cr, PAT Declines 22% YoY
Gujarat Kidney And Super Speciality Limited (GKSL) reported a marginal 2.5% YoY revenue growth for Q2 FY26, reaching ₹9.64 crore. However, Profit After Tax (PAT) for the quarter dropped significantly by 22% to ₹2.30 crore compared to the same period last year, indicating margin pressure. On a half-yearly basis, the performance remains positive with revenue up 13% and PAT up 10% YoY. Investors should note a sharp increase in current borrowings to ₹12.71 crore and rising trade receivables, which may impact liquidity.
முக்கிய அம்சங்கள்
Q2 Revenue from operations stood at ₹964.26 Lacs, a slight increase from ₹941.00 Lacs YoY.Quarterly Net Profit declined to ₹230.12 Lacs from ₹295.73 Lacs in the previous year's quarter.Half-year (H1) PAT grew by 10.1% to ₹620.10 Lacs compared to ₹563.13 Lacs in H1 FY25.Current borrowings escalated sharply to ₹1,270.71 Lacs from ₹95.53 Lacs in March 2025.Trade receivables increased to ₹1,862.59 Lacs as of September 2025, up from ₹1,279.91 Lacs in March 2025.
👀 கவனிக்க வேண்டியவை
Investors should exercise caution due to the significant rise in short-term debt and trade receivables, which could signal working capital stress. Monitor the company's ability to manage operational costs as quarterly margins have contracted despite stable revenue.
GKSL Acquires Parekhs Hospital Private Limited for ₹77 Crore
Gujarat Kidney And Super Speciality Limited (GKSL) has successfully executed the acquisition of a 100% stake in Parekhs Hospital Private Limited for ₹77 crore. The target entity, based in Ahmedabad, is a healthcare service provider with a steady revenue stream, reporting a turnover of ₹25.67 crore in FY 2024-25. This acquisition makes Parekhs Hospital a wholly-owned subsidiary of GKSL, aimed at strengthening the company's presence in the healthcare sector. The transaction was completed on March 22, 2026, through cash consideration.
முக்கிய அம்சங்கள்
Acquisition of 100% equity (2,55,000 shares) for a total cash consideration of ₹77 croreParekhs Hospital reported a turnover of ₹25.67 crore for FY 2024-25, showing stable performanceTarget company has a consistent financial track record with FY 2022-23 turnover at ₹24.06 croreStrategic expansion into the Ahmedabad healthcare market to diversify GKSL's business portfolioThe acquisition was completed on March 22, 2026, following an initial intimation in January 2026
👀 கவனிக்க வேண்டியவை
Investors should view this as a significant growth move, though the acquisition price of ₹77 crore for a ₹25.67 crore turnover business implies a high valuation multiple. Monitor the consolidated financial statements for improvements in margins and operational synergies post-integration.
GKSL Pays Rs 6.6 Lakh Penalty to BSE and NSE for Delayed Financial Results
Gujarat Kidney And Super Speciality Limited (GKSL) has informed the exchanges regarding a penalty payment of Rs 3,30,400 each to BSE and NSE, totaling Rs 6,60,800. The fine was imposed due to the company's failure to submit financial results within the prescribed timelines under Regulation 33 of SEBI LODR Regulations. The notices were received on March 17, 2026, and the company completed the payment via RTGS on March 21, 2026. While the monetary impact is limited, the delay in financial reporting is a negative signal regarding corporate governance and compliance discipline.
முக்கிய அம்சங்கள்
Total penalty of Rs 6,60,800 paid to stock exchanges (Rs 3,30,400 each to BSE and NSE).Penalty triggered by non-compliance with Regulation 33 for delayed submission of financial results.Notices were issued by the exchanges on March 17, 2026, and received late in the evening.Company confirmed the full payment of fines was completed on March 21, 2026, via RTGS.
👀 கவனிக்க வேண்டியவை
Investors should exercise caution and monitor if the company improves its reporting discipline in future quarters. It is important to review the delayed financial results once published to check for any underlying operational issues.
GKSL Appoints New Auditors; H1 FY26 Revenue Grows to ₹21.09 Cr, PAT at ₹6.20 Cr
Gujarat Kidney And Super Speciality Limited (GKSL) has appointed Mr. Dharmendra Bhaliya as Secretarial Auditor and Mr. Siddharth Atulbhai Shah as Internal Auditor for FY 2025-26 to strengthen corporate governance. The company reported a steady financial performance for the half-year ended September 30, 2025, with revenue from operations reaching ₹2,109.25 Lacs, up from ₹1,867.05 Lacs in the previous year. Net profit for the same period increased to ₹620.10 Lacs compared to ₹563.13 Lacs YoY. Additionally, the board ratified previous meeting outcomes that were delayed in submission to the exchanges.
முக்கிய அம்சங்கள்
Revenue from operations grew by 13% YoY to ₹2,109.25 Lacs for the half-year ended September 30, 2025.Profit After Tax (PAT) for H1 FY26 stood at ₹620.10 Lacs, a growth from ₹563.13 Lacs in H1 FY25.Total Assets increased significantly to ₹6,694.02 Lacs as of September 2025 from ₹4,907.23 Lacs in March 2025.Appointment of new Internal and Secretarial Auditors with 7 and 5 years of professional experience respectively.Current borrowings rose sharply to ₹1,270.71 Lacs from ₹95.53 Lacs in March 2025, indicating potential expansion or working capital needs.
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's ability to maintain margins given the rise in current borrowings and other expenses. The steady growth in PAT and strengthening of the audit team are positive signs for long-term governance.
GKSL Fined ₹3.30 Lakh by NSE and BSE for Delayed Q2 FY26 Financial Results
Gujarat Kidney And Super Speciality Limited (GKSL) has been penalized by both the National Stock Exchange (NSE) and BSE for non-compliance with SEBI Regulation 33. The exchanges have imposed a fine of ₹3,30,400 due to the company's failure to submit its financial results for the quarter ended September 30, 2025, within the prescribed timeline. While the company claims no significant impact on operations, the delay in reporting is a governance concern. The Board of Directors is expected to review the notice and provide further comments to the exchanges shortly.
முக்கிய அம்சங்கள்
NSE and BSE imposed a total fine of ₹3,30,400 including GST for regulatory non-compliance.The penalty pertains to the non-submission of financial results for the quarter ended September 30, 2025.Notices from both exchanges were received by the company on March 17, 2026.The company stated that the fine does not have a quantifiable impact on its financial or operational activities.The Board of Directors will shortly review the matter and provide official comments to the stock exchanges.
👀 கவனிக்க வேண்டியவை
Investors should exercise caution as delays in financial reporting can indicate internal administrative issues or poor corporate governance. Monitor the company's upcoming board comments to understand the reason behind the reporting delay.
GKSL Reports Q2 FY26 PAT of ₹2.30 Cr; Explains Delay in Financial Result Submission
Gujarat Kidney And Super Speciality Limited (GKSL) has released its delayed financial results for the quarter ended September 30, 2025, citing technical issues following its listing on December 30, 2025. For the quarter, the company reported revenue of ₹9.64 crore and a Profit After Tax (PAT) of ₹2.30 crore. On a half-yearly basis, revenue grew to ₹21.09 crore compared to ₹18.67 crore in the previous year, with PAT increasing to ₹6.20 crore from ₹5.63 crore. The company clarified that this was a first-time oversight due to being a newly listed entity.
முக்கிய அம்சங்கள்
Revenue from operations for Q2 FY26 stood at ₹964.26 Lacs, compared to ₹941.00 Lacs in the same period last year.Net Profit for the half-year ended September 30, 2025, rose to ₹620.10 Lacs from ₹563.13 Lacs YoY.Total Assets as of September 30, 2025, increased significantly to ₹6,694.02 Lacs from ₹4,907.23 Lacs in March 2025.Earnings Per Share (EPS) for the half-year ended September 2025 was reported at ₹1.22.The reporting delay was attributed to technical issues and the company's recent listing status as of December 30, 2025.
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's future compliance to ensure timely disclosures, while noting the steady growth in half-yearly profitability. The current delay appears to be an administrative lapse rather than a fundamental business issue.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
